TD Asset Management Inc Increases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

TD Asset Management Inc grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 172.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,500 shares during the quarter. TD Asset Management Inc’s holdings in Collegium Pharmaceutical were worth $483,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. ProShare Advisors LLC increased its position in shares of Collegium Pharmaceutical by 3.3% during the 1st quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock valued at $343,000 after purchasing an additional 281 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in shares of Collegium Pharmaceutical by 1.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after acquiring an additional 300 shares during the period. Texas Permanent School Fund Corp grew its stake in shares of Collegium Pharmaceutical by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after acquiring an additional 369 shares during the period. SummerHaven Investment Management LLC grew its stake in shares of Collegium Pharmaceutical by 1.3% during the 2nd quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock worth $1,120,000 after acquiring an additional 452 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Collegium Pharmaceutical by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock worth $1,137,000 after acquiring an additional 535 shares during the period.

Collegium Pharmaceutical Stock Up 2.7 %

Shares of NASDAQ COLL opened at $37.50 on Monday. The company has a market cap of $1.21 billion, a P/E ratio of 15.63 and a beta of 0.94. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The business has a 50-day simple moving average of $35.43 and a two-hundred day simple moving average of $35.40. Collegium Pharmaceutical, Inc. has a 52 week low of $20.95 and a 52 week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. The firm had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted $1.13 EPS. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.98% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. HC Wainwright increased their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their target price for the stock from $41.00 to $44.00 in a research note on Friday, June 7th. Piper Sandler restated a “neutral” rating and issued a $37.00 target price (down previously from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.